{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:03:04Z","timestamp":1791036184161,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.atherosclerosis.2008.04.037","type":"journal-article","created":{"date-parts":[[2008,4,30]],"date-time":"2008-04-30T15:09:17Z","timestamp":1209568157000},"page":"8-16","source":"Crossref","is-referenced-by-count":47,"title":["Prostanoid and isoprostanoid pathways in atherogenesis"],"prefix":"10.1016","volume":"201","author":[{"given":"Domenico","family":"Pratic\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib1","series-title":"Arteriosclerosis: a survey of problem","first-page":"1","author":"Aschoff","year":"1933"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib2","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1161\/CIRCULATIONAHA.106.179918","article-title":"Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"115","author":"Rosamond","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1161\/01.CIR.0000057982.50167.6E","article-title":"Relationships between low density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS)","volume":"107","author":"Vakkilainen","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ajhg.2007.11.001","article-title":"Genome-wide association study indentifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia","volume":"82","author":"Wallace","year":"2008","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib5","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejim.2005.11.002","article-title":"Fibrinolysis and cardiovascular risk factors: association with fibrinogen, lipids, and monocyte count","volume":"17","author":"Boudjeltia","year":"2006","journal-title":"Eur J Inter Med"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.atherosclerosis.2007.07.015","article-title":"Brachial artery vasoreactivity is associated with cross-sectional and longitudinal anatomical measures of atherosclerosis in post-menopausal women with coronary artery disease","volume":"196","author":"Gatto","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","article-title":"Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors. The Framingham Offspring Study","volume":"116","author":"Ingelsson","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib8","first-page":"1799","article-title":"Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. An individual participant meta-analysis","volume":"294","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib9","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/hc0902.104353","article-title":"Inflammation and atherosclerosis","volume":"105","author":"Libby","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tips.2005.10.001","article-title":"Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis","volume":"26","author":"Dogne","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/pr.56.3.3","article-title":"Cycloxygenase isozymes: the biology of prostaglandin synthesis and inhibition","volume":"56","author":"Simmons","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib12","doi-asserted-by":"crossref","first-page":"33157","DOI":"10.1074\/jbc.271.52.33157","article-title":"Prostaglandin endoperoxide H synthase (cyclooxygenases)-1 and -2","volume":"271","author":"Smith","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib13","doi-asserted-by":"crossref","first-page":"13926","DOI":"10.1073\/pnas.162468699","article-title":"Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic\/antipyretic drugs: cloning, structure and expression","volume":"99","author":"Chandrasekharan","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.molbrainres.2004.03.015","article-title":"Regional distribution of cyclooxygenase-3 mRNA in the rat central nervous system","volume":"126","author":"Kis","year":"2004","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.molbrainres.2003.09.006","article-title":"COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells","volume":"119","author":"Shaftel","year":"2003","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1124\/jpet.105.090944","article-title":"Cloning, expression, and functional characterization of human cyclooxygenase-1 splicing variants: evidence for intron 1 retention","volume":"315","author":"Qin","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00011-006-0083-z","article-title":"Cloning of cyclooxygenase-1b (putative COX-3) in mouse","volume":"55","author":"Kis","year":"2006","journal-title":"Inflamm Res"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib18","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.1016\/S0021-9258(18)98774-0","article-title":"TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase\/cyclooxygenase homologue","volume":"266","author":"Kujubu","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib19","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1073\/pnas.91.25.12013","article-title":"Pharmacological and biochemical demonstration of the role of cylcooxygenase 2 in inflammation and pain","volume":"91","author":"Seibert","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1161\/01.ATV.0000028816.13582.13","article-title":"Transcriptional and posttranslational regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells","volume":"22","author":"Inoue","year":"2002","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1081\/JDI-100104716","article-title":"Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy","volume":"23","author":"Khan","year":"2001","journal-title":"Ren Fail"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib22","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1523\/JNEUROSCI.21-16-05847.2001","article-title":"The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1","volume":"21","author":"Yaksh","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2174\/0929867043365260","article-title":"New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators","volume":"11","author":"Dogne","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2174\/0929867043365279","article-title":"New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators","volume":"11","author":"de Leval","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0140-6736(77)91655-5","article-title":"Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation","volume":"1","author":"Moncada","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transform prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib27","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/01.CIR.0000027816.54430.96","article-title":"Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor deficient mice","volume":"106","author":"Cyrus","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib28","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1161\/01.CIR.102.8.840","article-title":"Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis","volume":"102","author":"Belton","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib29","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/sj.bjp.0704416","article-title":"Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan","volume":"134","author":"Katugampola","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0014-2999(96)00478-5","article-title":"Thromboxane A2 receptor blockade suppresses intercellular adhesion molecule-1 expression by stimulated vascular endothelial cells","volume":"312","author":"Ishizuka","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00915886","article-title":"Mediation of augmented monocyte adhesiveness by thromboxane","volume":"12","author":"Spagnuolo","year":"1988","journal-title":"Inflammation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib32","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCULATIONAHA.104.513085","article-title":"C-reactive protein, interleukin-6, and soluble adhesion molecules predictors of progressive peripheral atherosclerosis in the general population: Edinburg Artery Study","volume":"112","author":"Tzoulaki","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/ATVBAHA.107.150250","article-title":"Activation of thromboxane receptor upregulates interleukin (IL) -1\u03b2-induced VCAM-1 expression through JNK signal","volume":"28","author":"Bayat","year":"2008","journal-title":"Arterioscl Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2008.04.037_bib34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.atherosclerosis.2007.06.031","article-title":"Up-regulation of thromboxane A2 receptor expression by lipid soluble smoking particles through post-transcriptional mechanisms","volume":"196","author":"Zhang","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0021-9150(73)90041-5","article-title":"Anti-inflammatory drugs in experimental atherosclerosis. I. Relative potencies for inhibiting plaque formation","volume":"17","author":"Bailey","year":"1973","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0024-3205(00)00950-4","article-title":"The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice","volume":"68","author":"Paul","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib37","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1073\/pnas.061607398","article-title":"Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice","volume":"98","author":"Pratic\u00f2","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib38","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1161\/01.CIR.0000104565.78013.AD","article-title":"Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis","volume":"108","author":"Belton","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomized trials of anti-platelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"Br Med J"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0232-1513(11)80001-0","article-title":"Atherosclerosis in the aorta of hypercholesterolemic rabbits and the influence of daltroban","volume":"41","author":"Metz","year":"1991","journal-title":"Exp Pathol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib42","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.ATV.20.7.1724","article-title":"The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis","volume":"20","author":"Cayatte","year":"2000","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib43","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/eurheartj\/ehi175","article-title":"Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition\u2014a magnetic resonance imaging study","volume":"26","author":"Viles-Gonzales","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.atherosclerosis.2005.02.034","article-title":"S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits","volume":"183","author":"Worth","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib45","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1160\/TH07-04-0272","article-title":"A thromboxane A2\/prostgalndin H2-receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis","volume":"98","author":"Vilahur","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejphar.2006.12.024","article-title":"A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice","volume":"561","author":"Cyrus","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib47","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood-2006-08-044990","article-title":"Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDL r KO mice","volume":"109","author":"Cyrus","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib48","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1182\/blood.V96.12.3823","article-title":"Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis","volume":"96","author":"Pratic\u00f2","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib49","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2174\/138161206776055949","article-title":"Coxibs and cardiovascular side-effects: from light to shadow","volume":"12","author":"Dogne","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib50","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1172\/JCI27540","article-title":"Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function","volume":"116","author":"Cheng","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib51","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1161\/hc3301.092790","article-title":"Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries","volume":"104","author":"Hennan","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/01.HYP.0000140924.91479.03","article-title":"Inhibition of cyclooxygenase-2 in the rat renal medulla leads to sodium-sensitive hypertension","volume":"44","author":"Zewde","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib53","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1161\/01.CIR.0000145613.01188.0B","article-title":"Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2","volume":"110","author":"Pidgeon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib54","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/41780","article-title":"Altered pain perception and inflammatory response in mice lacking prostacyclin receptor","volume":"388","author":"Murata","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib55","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1161\/01.CIR.0000014927.74465.7F","article-title":"Cycloxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice","volume":"105","author":"Burleigh","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib56","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/S0735-1097(03)00304-8","article-title":"Effects of MF-tricyclic, a selective cycloxygenase-2 inhibitor, on atherogenesis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice","volume":"41","author":"Rott","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib57","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0008-6363(03)00464-4","article-title":"Chronic inhibition of cycloxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis","volume":"60","author":"Bea","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1080\/140174302762659094","article-title":"No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice","volume":"36","author":"Olensen","year":"2002","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib59","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00109-007-0162-9","article-title":"The effects of COX-2 selective and non-selective NSAIDs on the initiation and progression of atherosclerosis in apoE\u2212\/\u2212 mice","volume":"85","author":"Metzner","year":"2007","journal-title":"J Mol Med"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(99)00257-9","article-title":"F2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo","volume":"147","author":"Pratic\u00f2","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib61","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1043-2760(01)00411-8","article-title":"The isoprostanes in biology and medicine","volume":"12","author":"Pratic\u00f2","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib62","doi-asserted-by":"crossref","first-page":"8919","DOI":"10.1074\/jbc.271.15.8919","article-title":"Generation of 8-epi PGF2\u03b1 by human monocytes: discriminant production by reactive oxygen species and PG G\/H S-2","volume":"271","author":"Pratic\u00f2","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib63","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1161\/01.CIR.0000014762.06201.06","article-title":"Is the oxidative modification hypothesis relevant to human atherosclerosis?","volume":"105","author":"Steinberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/00041433-199810000-00008","article-title":"Oxidized phospholipids and isoprostanes in atherosclerosis","volume":"9","author":"Witztum","year":"1998","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib65","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"New Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib66","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1172\/JCI119735","article-title":"Localization of distinct F2-isoprostanes in human atherosclerotic lesions","volume":"100","author":"Pratic\u00f2","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1050-1738(01)00099-8","article-title":"Lipid peroxidation in mouse models of atherosclerosis","volume":"11","author":"Pratic\u00f2","year":"2001","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib68","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1161\/01.CIR.99.2.224","article-title":"In vivo formation of 8-iso-prostaglandin F2-alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation","volume":"99","author":"Davi","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib69","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0735-1097(00)01040-8","article-title":"Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA","volume":"37","author":"Iuliano","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib70","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1161\/01.CIR.102.9.1007","article-title":"Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina","volume":"102","author":"Cipollone","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1172\/JCI3985","article-title":"The relationship between hydroxyeicosatetraenoic acids and F2-isoprostanes to plaque instability in human carotid atherosclerosis","volume":"103","author":"Mallat","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib72","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/2685","article-title":"Vitamin E suppresses isoprostanes generation in vivo and reduces atherogenesis in ApoE-deficient mice","volume":"4","author":"Pratic\u00f2","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib73","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1161\/01.CIR.0000055186.40785.C4","article-title":"Vitamin E reduces progression of atherosclerosis in low-density lipoprotein receptor-deficient mice with established vascular lesions","volume":"107","author":"Cyrus","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib74","doi-asserted-by":"crossref","first-page":"13830","DOI":"10.1073\/pnas.240462697","article-title":"Increased atherosclerosis in hyperlipidemic mice deficient in \u03b1-tocopherol transfer protein and vitamin E","volume":"97","author":"Terasawa","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib75","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.CIR.0000116761.93647.30","article-title":"Urinary 8-iso-prostaglandin F2\u03b1 as a risk marker in patients with coronary heart disease","volume":"109","author":"Schwedhelm","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2008.04.037_bib76","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.freeradbiomed.2007.10.004","article-title":"F2-isoprostanes are not just markers of oxidative stress","volume":"44","author":"Comporti","year":"2008","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib77","doi-asserted-by":"crossref","first-page":"14916","DOI":"10.1074\/jbc.271.25.14916","article-title":"Local amplification of platelet function by 8-epi Prostaglandin F2\u03b1","volume":"271","author":"Pratic\u00f2","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib78","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1161\/CIRCULATIONAHA105.562223","article-title":"Involvement of thromboxane receptor in the proatherogenic affect of isoprostane F2\u03b1-III. Evidence from apolipoprotein E- and LDL receptor-deficient mice","volume":"112","author":"Tang","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib79","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/S0735-1097(03)00048-2","article-title":"Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin","volume":"41","author":"Belhassen","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib80","doi-asserted-by":"crossref","first-page":"15735","DOI":"10.1074\/jbc.M910376199","article-title":"Combined serum paroxonase knockout\/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis","volume":"275","author":"Shih","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib81","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1172\/JCI5897","article-title":"Disruption of 12\/15 LO-lipoxygenase gene diminishes atherosclerosis in apoE-deficient mice","volume":"103","author":"Cyrus","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.atherosclerosis.2008.04.037_bib82","doi-asserted-by":"crossref","unstructured":"Tang L, Ding T, Pratic\u00f2 D. Additive anti-atherogenic effect of thromboxane receptor antagonism with 12\/15 lipoxygenase gene disruption in apolipoprotein E deficient mice. Atherosclerosis 2008; Jan 17 [Epub ahead of print].","DOI":"10.1016\/j.atherosclerosis.2007.11.038"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915008002529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915008002529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T06:17:23Z","timestamp":1631168243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915008002529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0021915008002529"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.04.037","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}